Table 5.
Results for demographic and clinical factors (qualitative)
| Group | Total score | Reduced sodium intake | Appointment keeping | Medication taking |
|---|---|---|---|---|
| Female | 19 (17–22) | 5 (4–5) | 3 (2–4) | 11 (10–13.25) |
| Male | 20 (18–23) | 5 (5–6) | 3.5 (2–4) | 11.5 (10–14) |
| P-value* | 0.22 | 0.01 | 0.71 | 0.36 |
| Married or living together (A) | 18 (16.25–20) | 5 (4–5) | 3 (2–4) | 10 (9–12) |
| Single or divorced (B) | 20 (18–21.5) | 5 (4.5–5) | 3 (2.5–4) | 12 (10.5–12.5) |
| Widowed (C) | 22 (19–23) | 5 (4–5) | 4 (3–4) | 13 (10–15) |
| P-value* | <0.001 | 0.752 | 0.04 | <0.001 |
| Post hoc** | C>A | – | C>A | C>A |
| Primary or none (A) | 22 (18–24.5) | 5 (4–6) | 3 (2–4) | 13 (10–15) |
| Secondary (B) | 20 (18–22) | 5 (4–5) | 4 (3–4) | 11 (10–13) |
| Vocational or higher (C) | 18 (16–19) | 5 (4–5) | 2 (2–4) | 10 (9–11) |
| P-value* | <0.00 | 0.38 | 0.01 | <0.00 |
| Post hoc** | A.B>C | – | A.B>C | A>B>C |
| Employed (A) | 18 (16–20) | 5 (4–6) | 2.5 (2–3.75) | 10 (9–11.75) |
| Retired (B) | 20 (18–23) | 5 (4–5) | 4 (2–4) | 12 (10–14) |
| Annuitant (C) | 19 (17.75–22) | 5 (4.75–5) | 3 (2–4) | 11.5 (9.75–13) |
| P-value* | 0.06 | 0.43 | 0.02 | 0.03 |
| Post hoc** | – | – | B>A | B>A |
| Living alone or in an organized institution (A) | 22 (19–24) | 5 (4–5) | 4 (3–5) | 13 (10–15) |
| Living with family (B) | 18 (17–21) | 5 (4–5.75) | 3 (2–4) | 11 (9–12.75) |
| P-value* | <0.00 | 0.79 | <0.00 | <0.00 |
| Prehypertension (A) | 19 (16–22.75) | 4.5 (4–5) | 3 (2–4) | 11 (10–13) |
| Stage I HT (B) | 20 (18–23) | 5 (4–5) | 3 (2–4) | 12 (10–14) |
| Stage II HT (C) | 18 (17–20) | 5 (4–5) | 3 (2–4) | 10 (9–12) |
| P-value* | 0.043 | 0.164 | 0.808 | 0.025 |
| Post hoc** | B>C | – | – | B>C |
| Non-smoker | 20 (18–23) | 5 (4–5) | 3 (2–4) | 11 (10–14) |
| Ex-smoker | 18 (17–21) | 5 (4–5) | 3 (2–4) | 10 (9–13) |
| Smoker | 18 (17–20) | 5 (4–6) | 3 (2–4) | 10 (9–12) |
| P-value* | 0.066 | 0.127 | 0.456 | 0.052 |
| Post hoc** | – | – | – | – |
| Abstinent | 20 (17–22) | 5 (4–5) | 3 (2–4) | 11 (10–14) |
| Non-abstinent | 19 (17–22) | 5 (4–6) | 3 (2–4) | 11 (10–12.5) |
| P-value* | 0.31 | 0.18 | 0.06 | 0.35 |
| Lack of diabetes | 19 (17–22) | 5 (4–5) | 3 (2–4) | 11 (9–14) |
| Diabetes | 20 (18–23) | 5 (4–5.25) | 3 (2–4) | 11 (10–14) |
| P-value* | 0.46 | 0.46 | 0.37 | 0.28 |
| Lack of hypercholesterolemia | 19 (17–23) | 5 (4–5) | 3 (2–4) | 11 (10–14) |
| Hypercholesterolemia | 20 (18.75–22) | 5 (4–5.25) | 4 (3–5) | 11 (10–13) |
| P-value* | 0.09 | 0.5 | <0.00 | 0.95 |
| Lack of coronary artery disease | 18 (17–22) | 5 (4–5) | 3 (2–4) | 11 (9–13) |
| Coronary artery disease | 21 (19–23) | 5 (4–5) | 4 (3–5) | 13 (10–14) |
| P-value* | 0.00 | 0.78 | 0.01 | 0.01 |
| Lack of renal failure | 19.5 (17–22.75) | 5 (4–5) | 3 (2–4) | 11 (10–14) |
| Renal failure | 19 (17.75–22) | 4.5 (4–5.25) | 3 (3–4) | 10.5 (9–14) |
| P-value* | 0.72 | 0.34 | 0.55 | 0.51 |
| Lack of rheumatic diseases | 19 (17–22) | 5 (4–5) | 3 (2–4) | 11 (10–14) |
| Rheumatic diseases | 21 (18–22) | 5 (4–5) | 3 (3–5) | 12 (10–13) |
| P-value* | 0.32 | 0.66 | 0.33 | 0.62 |
| Lack of AA | 20 (17–22.25) | 5 (4–5) | 3 (2–4) | 11 (10–14) |
| AA | 18 (18–18.75) | 5 (5–5) | 2 (2–2.75) | 11 (10.25–11.75) |
| P-value* | 0.23 | 0.6 | 0.03 | 0.53 |
| Lack of BA | 20 (17–23) | 5 (4–5) | 3 (2–4) | 11 (10–14) |
| BA | 19 (17.75–22) | 5 (4–6) | 3 (2–4) | 11 (10–13.25) |
| P-value* | 0.47 | 0.87 | 0.08 | 0.66 |
| Lack of CCB | 19.5 (17–22) | 5 (4–5) | 3 (2–4) | 11 (10–14) |
| CCB | 19 (17.25–22) | 5 (4–5) | 3 (2–4) | 12 (10–13) |
| P-value* | 0.95 | 0.69 | 0.49 | 0.99 |
| Lack of ARB | 19 (17–22) | 5 (4–5) | 3 (2–4) | 11 (10–14) |
| ARB | 23 (17.5–25.5) | 5 (4–5.5) | 4 (3–4) | 14 (10–16) |
| P-value* | 0.17 | 0.81 | 0.4 | 0.14 |
| Lack of TD | 19 (17–21) | 5 (4–5) | 3 (2–4) | 10 (9–13) |
| TD | 22 (18–24) | 5 (4–5) | 4 (2–4) | 13 (11–15) |
| P-value* | <0.00 | 0.32 | 0.17 | <0.00 |
| Lack of ACEI | 20 (18–23) | 5 (4–6) | 3 (2–4) | 12 (10–14) |
| ACEI | 19 (17–22) | 5 (4–5) | 3 (2–4) | 11 (9.25–13.75) |
| P-value* | 0.15 | 0.25 | 0.71 | 0.13 |
| Monotherapy | 19 (17–21) | 5 (4–5) | 3 (2–4) | 10 (10–13) |
| Polytherapy | 20 (18–23.5) | 5 (4–5) | 3 (2–4) | 12 (10–14) |
| P-value* | 0.08 | 0.54 | 0.40 | 0.04 |
Notes: Data are represented as median (Q1–Q3).
*
Mann–Whitney test and Kruskal–Wallis test.
**
The Dunn test (results for post hoc analysis). P, level of statistical significance. –, no relationship in post hoc analyses between A, B, and C for reduced sodium intake subscale.
Abbreviations: AA, alpha-adrenolytic; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; BA, beta-adrenolytic; CCB, calcium channel blocker; HT, hypertension; Q1, first quartile; Q1, third quartile; TD, thiazide diuretic.